Estimated glomerular filtration rate is a biomarker of cognitive impairment in Parkinson’s disease
Yi Qu, Qixiong Qin, Dan-Lei Wang, Jiangting Li, Jingwei Zhao, Ke An, Jingyi Li, Zhijuan Mao, Zhe Min, Yongjie Xiong, Zheng Xue
Abstract
Backgrounds The relationship between kidney function and cognitive impairment in Parkinson’s disease (PD) is poorly understood and underexplored. This study aims to explore whether renal indices can serve as indicators to monitor the cognitive impairment of PD. Methods A total of 508 PD patients and 168 healthy controls from the Parkinson’s Progression Markers Initiative (PPMI) were recruited, and 486 (95.7%) PD patients underwent longitudinal measurements. The renal indicators including serum creatinine (Scr), uric acid (UA), and urea nitrogen, as well as UA/Scr ratio and estimated glomerular filtration rate (eGFR), were measured. Cross-sectional and longitudinal associations between kidney function and cognitive impairment were evaluated using multivariable-adjusted models. Results eGFR was associated with lower levels of cerebrospinal fluid (CSF) A β 1–42 ( p = 0.0156) and α-synuclein ( p = 0.0151) and higher serum NfL ( p = 0.0215) in PD patients at baseline. Longitudinal results showed that decreased eGFR predicted a higher risk of cognitive impairment (HR = 0.7382, 95% CI = 0.6329–0.8610). Additionally, eGFR decline was significantly associated with higher rates of increase in CSF T-tau ( p = 0.0096), P-tau ( p = 0.0250), and serum NfL ( p = 0.0189), as well as global cognition and various cognitive domains ( p < 0.0500). The reduced UA/Scr ratio was also linked to higher NfL levels ( p = 0.0282) and greater accumulation of T-tau ( p = 0.0282) and P-tau ( p = 0.0317). However, no significant associations were found between other renal indices and cognition. Conclusion eGFR is altered in PD subjects with cognitive impairment, and predict larger progression of cognitive decline. It may assist identifying patients with PD at risk of rapid cognitive decline and have the potential to monitoring responses to therapy in future clinical practice.